腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征的疗效

蔡少康; 兰伟文; 董军立; 姚宪宝; 蔡毅

doi:10.11659/jjssx.05E023032

您当前的位置：

首页 >

文章列表页 >

腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征的疗效

临床研究 | 更新时间：2023-11-24

- 腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征的疗效
- Efficacy of celiac plexus destruction combined with duloxetine in the treatment of centrally mediated abdominal pain syndrome
- 局解手术学杂志 2023年32卷第11期页码：994-997
- 作者机构：
  
  华中科技大学同济医学院附属武汉市中心医院疼痛科，湖北武汉 430061
- 作者简介：
  
  蔡毅，E-mail：517221634@qq.com
- 基金信息：
  
  武汉市卫生计划委员会基金项目(WH21Z58)
- DOI：10.11659/jjssx.05E023032
  中图分类号： R441.1
- 纸质出版日期：2023-11-25，
  
  收稿日期：2023-05-08，
扫描看全文
蔡少康,兰伟文,董军立等.腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征的疗效[J].局解手术学杂志,2023,32(11):994-997.

CAI Shao-kang,LAN Wei-wen,DONG Jun-li,et al.Efficacy of celiac plexus destruction combined with duloxetine in the treatment of centrally mediated abdominal pain syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(11):994-997.
蔡少康,兰伟文,董军立等.腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征的疗效[J].局解手术学杂志,2023,32(11):994-997. DOI： 10.11659/jjssx.05E023032.

CAI Shao-kang,LAN Wei-wen,DONG Jun-li,et al.Efficacy of celiac plexus destruction combined with duloxetine in the treatment of centrally mediated abdominal pain syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(11):994-997. DOI： 10.11659/jjssx.05E023032.

摘要

目的

观察腹腔神经丛毁损术联合度洛西汀治疗中枢介导性腹痛综合征（CAPS）的临床疗效及安全性。

方法

纳入我院收治的40例CAPS患者，将其分为观察组和对照组，对照组采用度洛西汀治疗，观察组在对照组治疗的基础上加用腹腔神经丛毁损术治疗。分别于治疗前及治疗后1周、4周、12周、24周采用症状自评量表（SCL-90）评估患者心理健康状态，采用简化McGill疼痛问卷（SF-MPQ）评估患者腹痛缓解情况，比较2组患者治疗后并发症发生率。

结果

与治疗前比较，观察组治疗后1~12周SF-MPQ评分显著下降（

0.05），治疗后24周下降极为显著（

0.01），而对照组在治疗后12周才显著下降（

0.05）；治疗后1周、4周、12周，观察组SF-MPQ评分与对照组比较，差异无统计学意义（

0.05），但治疗后24周观察组优于对照组（

0.05）。2组患者治疗后12周内SCL-90评分组间比较差异无统计学意义（

0.05），2组患者治疗后24周SCL-90评分较治疗前显著下降（

0.05），但组间比较差异无统计学意义（

0.05）。2组患者并发症发生率比较差异无统计学意义（

0.05）。

结论

腹腔神经丛毁损术联合度洛西汀治疗CAPS可以快速且有效地缓解患者症状，且有良好的安全性。

Abstract

Objective

To observe the clinical efficacy and safety of celiac plexus destruction combined with duloxetine in the treatment of centrally mediated abdominal pain syndrome （CAPS）.

Methods

A total of 40 CAPS patients admitted to our hospital were divided into the observation group and the control group. The control group was treated with duloxetine， and the observation group was treated with celiac plexus destruction on the basis of the control group. The mental health states of patients before treatment and 1 week， 4 weeks， 12 weeks， and 24 weeks after treatment were evaluated by the symptom checklist 90 （SCL-90）， respectively. The short-form McGill pain questionnaire （SF-MPQ） was used to evaluate the relief of abdominal pain. The incidence of complications after treatment was compared between the two groups of patients.

Results

Compared with before treatment， the SF-MPQ scores 1 to 12 weeks after treatment in the observation group decreased significantly （

0.05）， and the decrease was extremely significant 24 weeks after treatment （

0.01）； while the SF-MPQ score in the control group only significantly decreased 12 weeks after treatment （

0.05）. There was no statistically significant difference in the SF-MPQ scores after 1 week， 4 weeks and 12 weeks of treatment between the observation group and the control group （

0.05）， but the observation group was better than the control group 24 weeks after treatment （

0.05）. There was no statistically significant difference in the SCL-90 scores within 12 weeks after treatment between the two groups （

0.05）， and the SCL-90 scores 24 weeks after treatment of the two groups decreased significantly compared with those before treatment （

0.05）， but there was no statistically significant difference between the two groups （

0.05）. There was no statistically significant difference in the incidence of complications between the two groups （

0.05）.

Conclusion

Celiac plexus destruction combined with duloxetine in the treatment of CAPS can relieve the symptoms of patients quickly and effectively， and has a good safety.

关键词

腹腔神经丛毁损术中枢介导性腹痛综合征功能性腹痛综合征度洛西汀

Keywords

celiac plexus destructioncentrally mediated abdominal pain syndromefunctional abdominal pain syndromeduloxetine

references

Keefer L，Drossman DA，Guthrie E，et al.Centrally mediated disorders of gastrointestinal pain［J］.Gastroenterology，2016，19：S0016-5085（16）00225-0.doi：10.1053/j.gastro.2016.02.034http://dx.doi.org/10.1053/j.gastro.2016.02.034.

Sperber AD，Drossman DA.Review article：the functional abdominal pain syndrome［J］.Aliment Pharmacol Ther，2011，33（5）：514-524.doi：10.1111/j.1365-2036.2010.04561.xhttp://dx.doi.org/10.1111/j.1365-2036.2010.04561.x.

卫伟,杨光宇,贾红影.CT引导下腹腔神经丛无水乙醇毁损术对癌因性上腹痛的镇痛效果[J].癌症进展,2023,21(4):391-394.doi:10.11877/j.issn.1672-1535.2023.21.04.10http://dx.doi.org/10.11877/j.issn.1672-1535.2023.21.04.10.

Schmulson MJ，Drossman DA.What is new in Rome IV［J］.J Neurogastroenterol Motil，2017，23（2）：151-163.doi：10.5056/jnm16214http://dx.doi.org/10.5056/jnm16214.

Tack J，Drossman DA.What's new in Rome IV？［J］.Neurogastroenterol Motil，2017，29（9）：e13053.doi：10.1111/nmo.13053http://dx.doi.org/10.1111/nmo.13053.

Aziz Q，Schnitzler A，Enck P.Functional neuroimaging of visceral sensation［J］.J Clin Neurophysiol，2000，17（6）：604-612.doi：10.1097/00004691-200011000-00006http://dx.doi.org/10.1097/00004691-200011000-00006.

Kiguchi N，Kobayashi Y，Kadowaki Y，et al.Vascular endothelial growth factor signaling in injured nerves underlies peripheral sensitization in neuropathic pain［J］.J Neurochem，2014，129（1）：169-178.doi：10.1111/jnc.12614http://dx.doi.org/10.1111/jnc.12614.

Schuttert I，Timmerman H，Petersen KK，et al.The definition，assessment，and prevalence of （human assumed） central sensitisation in patients with chronic low back pain：a systematic review［J］.J Clin Med，2021，10（24）：5931.doi：10.3390/jcm10245931http://dx.doi.org/10.3390/jcm10245931.

傅青雯，尤浩军，雷静.神经病理性疼痛发生机制的研究进展［J］.生命科学研究，2023，27（2）：139-146.doi：10.16605/j.cnki.1007-7847.2022.07.0176http://dx.doi.org/10.16605/j.cnki.1007-7847.2022.07.0176.

郑义，康凯，王智杰，等.中枢敏化及其对膝关节骨关节炎临床治疗的影响［J］.中华老年骨科与康复电子杂志，2020，6（4）：243-247.doi：10.3877/cma.j.issn.2096-0263.2020.04.010http://dx.doi.org/10.3877/cma.j.issn.2096-0263.2020.04.010.

Hsu ES.Acute and chronic pain management in fibromyalgia：updates on pharmacotherapy［J］.Am J Ther，2011，18（6）：487-509.doi：10.1097/MJT.0b013e3181d6b6d4http://dx.doi.org/10.1097/MJT.0b013e3181d6b6d4.

赵丽玲，黄彦珊，王利，等.SNRIs类药物应用于神经病理性疼痛的临床应用进展［J/OL］.医药导报：1-11［2023-04-30］.http：//kns.cnki.net/kcm-s/detail/42.1293.r.20230320.0943.008.htmlhttp://kns.cnki.net/kcm-s/detail/42.1293.r.20230320.0943.008.html.

Choi JW，Joo EY，Lee SH，et al.Radiofrequency thermocoagulation of the thoracic splanchnic nerve in functional abdominal pain syndrome -a case report［J］.Korean J Anesthesiol，2011，61（1）：79-82.doi：10.4097/kjae.2011.61.1.79http://dx.doi.org/10.4097/kjae.2011.61.1.79.

Cornman-Homonoff J，Holzwanger DJ，Lee KS，et al.Celiac plexus block and neurolysis in the management of chronic upper abdominal pain［J］.Semin Intervent Radiol，2017，34（4）：376-386.doi：10.1055/s-0037-1608861http://dx.doi.org/10.1055/s-0037-1608861.

Kambadakone A，Thabet A，Gervais DA，et al.CT-guided celiac plexus neurolysis：a review of anatomy，indications，technique，and tips for successful treatment［J］.Radiographics，2011，31（6）：1599-1621.doi：10.1148/rg.316115526http://dx.doi.org/10.1148/rg.316115526.

Urits I，Jones MR，Orhurhu V，et al.A comprehensive review of the celiac plexus block for the management of chronic abdominal pain［J］.Curr Pain Headache Rep，2020，24（8）：42.doi：10.1007/s11916-020-00878-4http://dx.doi.org/10.1007/s11916-020-00878-4.

孙成建，王彦华，王松，等.不同剂量无水乙醇腹腔神经丛阻滞治疗上腹癌痛的疗效观察［J］.中国医学影像技术，2014，30（10）：1536-1540.doi：10.13929/j.1003-3289.2014.10.026http://dx.doi.org/10.13929/j.1003-3289.2014.10.026.

王玥，许婷，乔月芹，等.度洛西汀治疗中枢介导的腹痛综合征的疗效研究［J］.胃肠病学，2020，25（11）：666-669.doi：10.3969/j.issn.1008-7125.2020.11.005http://dx.doi.org/10.3969/j.issn.1008-7125.2020.11.005.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据